1. Sakane T, Takeno M, Suzuki N, Inaba G. Behç et's disease. N Engl J Med. 1999; 341:1284–1291.
2. Criteria for diagnosis of Behç et's disease. International Study Group for Behç et's Disease. Lancet. 1990; 335:1078–1080.
3. Kaklamani VG, Tzonou A, Kaklamanis PG. Behç et's disease associated with malignancies. Report of two cases and review of the literature. Clin Exp Rheumatol. 2005; 23(4 suppl 38):S35–S41.
4. Kaloterakis A, Stavrianeas NG, Karagianni IN, et al. Ada-mantiades-Behç et's disease coexisting with acute myeloblastic leukaemia. Br J Dermatol. 1997; 137:317–318.
5. Tassies D, Cervantes F, Feliu E, Cabal G, Martinez Orozco F, Rozman C. Behç et's disease with an onset prior to the appearance of chronic myeloid leukemia. Med Clin (Barc). 1992; 99:67–68.
6. Abe T, Yachi A, Yabana T, et al. Gastric non-Hodgkin's lymphoma associated with Behç et's disease. Intern Med. 1993; 32:663–667.
7. Kawabata H, Sawaki T, Kawanami T, et al. Myelodysplastic syndrome complicated with inflammatory intestinal ulcers: significance of trisomy 8. Intern Med. 2006; 45:1309–1314.
Article
8. Suk KT, Kim HS, Kim JM, et al. A case of intestinal Behç et's disease associated with myelodysplastic syndrome with chromosomal trisomy 8. Korean J Gastroenterol. 2003; 41:229–233.
9. Ahn JK, Cha HS, Koh EM, et al. Behç et's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology (Oxford). 2008; 47:1228–1230.
10. Tada Y, Koarada S, Haruta Y, Mitamura M, Ohta A, Nagasawa K. The association of Behç et's disease with myelodysplastic syndrome in Japan: a review of the literature. Clin Exp Rheumatol. 2006; 24(5 suppl 42):S115–S119.
11. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelody-splasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest. 2004; 34:690–700.
Article
12. Hsu HC, Lee YM, Tsai WH, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology. 2002; 63:64–69.
Article
13. Hadda V, Pandey BD, Gupta R, Goel A. Azathioprine induced pancytopenia: a serious complication. J Postgrad Med. 2009; 55:139–140.
Article
14. Desai SB, Furst DE. Problems encountered during anti-tu-mour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006; 20:757–790.
Article
15. Maciejewski JP, Selleri C. Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma. 2004; 45:433440.
Article
16. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002; 99:3129–3135.
Article
17. Chen G, Zeng W, Miyazato A, et al. Distinctive geneexpression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood. 2004; 104:4210–4218.
18. Nonami A, Takenaka K, Sumida C, et al. Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Behç et's disease by up-front cord blood transplantation. Intern Med. 2007; 46:1753–1756.